AstraZeneca Mexico – Ugo de Jacobis, President
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives. The company focuses on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). It is also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. In Mexico the company relies on manufacturing capabilities and a staff of 150 people.
Contact details
AstraZeneca S.A. de C.V.
Periférico Sur No. 4305, 5to piso
Col. Jardines de la Montaña, Del. Tlalpan
CP 14210 México DF
MEXICO
Tel: +52 (55) 5374 9600
Website: www.astrazeneca.com/mexico
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
There have been a lot of changes in the Mexican pharmaceutical industry in the last four to five years, most notably the new drug registration process being put in place.…
Dr. Teresa Corona Vázquez, the general director of one of the leading neuroscience institutions in Latin America, details their most important research partnerships and achievements, notably with regards to neurodegenerative…
Juan Fransisco Millán Sobaranes of Cetifarma, the council created by the pharmaceutical industry in Mexico for ethics and transparency, discussed the agency’s major milestones and its main priorities for ensuring…
Building on the continuous improvements of the Federal Commission for the Protection Against Sanitary Risk (Cofepris) over the last few years, its recently-appointed Federal Commissioner Julio Sánchez y Tépoz reveals…
Socorro España Lomelí, executive director of Mexico’s National Association of Drug Manufacturers (ANAFAM), details her strategic priorities with regards to the promotion of the industry’s export strategy, the implementation of…
Rafael Gual, general director of CANIFARMA, the chamber that brings together multinational and local drug manufacturers, details how the organization is currently intensifying its efforts to ensure the pharmaceutical industry…
Although the country is moving in the right direction with regards to universal coverage, a number of barriers to effective implementation remain. 57.3 million previously uninsured Mexicans are now enrolled…
PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of…
Two companies from two different countries chose Mexico as their entry market to Latin America. The heads of these companies spoke to PharmaBoardroom about their market entry strategies. Edmée Stenken,…
The industry of medical devices is soaring in Mexico. The general manager of ConvaTec discusses strategic priorities, new approaches and how reduced time to market is feeding the double-digit growth…
IMS Health recently released its World Review 2015. The new general manager of North Latin America shares the company’s assessment on the performance of the Mexican pharmaceutical market for 2014,…
The industry of medical devices is still not very well understood. Pablo Dávila shared with us his overview on the Mexican market, how the Mexican Association of Innovative Medical Device…
The technical & RA director and the managing director of Qually Corporacion explain how authorized third partied act as an extension of the regulative body, Cofepris, helping to assure that…
See our Cookie Privacy Policy Here